CRISPR
The firm now anticipates accelerating its commercialization phase by one to two years and will mix and match its technologies going forward.
Sherlock Biosciences to Acquire Sense Biodetection
The firms intend to combine Sherlock's CRISPR technology and Sense's rapid molecular amplification chemistries, accelerating Sherlock's go-to-market strategy.
Sherlock Biosciences Awarded $2M by Gates Foundation for Instrument-Free Diagnostics
The funding will be used to advance the firm's assay menu as well as to develop an integrated prototype diagnostic device.
UPDATE: Sherlock Biosciences, Tolo Biotech Reach Another CRISPR Licensing Agreement for Dx
The deal builds on an earlier agreement between the firms covering Sherlock's Cas12 and Cas13 CRISPR diagnostic methods.
The firm plans to use the method to develop and commercialize assays for infectious diseases including sexually transmitted infections.
Sep 2, 2022
May 31, 2022
Aug 10, 2021
Jun 29, 2021
Apr 26, 2021